sharesgurusharesguru
Account menu
sharesguru
MEDANTA

MEDANTA - Global Health Limited Share Price

Healthcare Services

1200.90+4.00(+0.33%)
Market Closed as of Jun 5, 2025, 15:30 IST

Valuation

Market Cap32.25 kCr
Price/Earnings (Trailing)63.58
Price/Sales (Trailing)8.83
EV/EBITDA35.24
Price/Free Cashflow83.13
MarketCap/EBT49.1

Fundamentals

Revenue (TTM)3.65 kCr
Rev. Growth (Yr)12.28%
Rev. Growth (Qtr)-1.57%
Earnings (TTM)507.29 Cr
Earnings Growth (Yr)15.64%
Earnings Growth (Qtr)9.2%

Profitability

Operating Margin17.98%
EBT Margin17.98%
Return on Equity16.14%
Return on Assets11.25%
Free Cashflow Yield1.2%

Price to Sales Ratio

Latest reported: ₹9

Revenue (Last 12 mths)

Latest reported: ₹4 kCr

Net Income (Last 12 mths)

Latest reported: ₹507 Cr
Pros

Growth: Good revenue growth. With NA% growth over past three years, the company is going strong.

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Profitability: Recent profitability of 14% is a good sign.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Size: Market Cap wise it is among the top 20% companies of india.

Cons

Dividend: Stock hasn't been paying any dividend.

Momentum: Stock has a weak negative price momentum.

Technicals: SharesGuru indicator is Bearish.

The Good, Bad and Ugly
Growth
Measures how quickly a company is expanding through metrics like revenue growth, earnings growth, and cash flow growth over time. Strong growth can indicate future potential.
Profitability
Shows how efficiently a company turns business activities into profit, using metrics like profit margins, return on equity (ROE), and return on assets (ROA).
Size
Indicates the company's market presence through metrics like market capitalization, total assets, and revenue. Size can influence stability and market influence.
Dilution Rank
Tracks how much the company's shares have increased or decreased over time. Lower dilution means existing shareholders maintain stronger ownership stakes.
Balance Sheet
Evaluates the company's financial health by analyzing assets, debts, and equity. A strong balance sheet indicates financial stability and flexibility.
Momentum
Measures the strength and speed of price movements, showing whether the stock is gaining or losing market favor over different time periods.
Technicals
Analyzes price patterns, trading volumes, and other market indicators to identify potential trading opportunities and market trends.
Smart Money
Tracks the investment activities of institutional investors, hedge funds, and other large financial players who often have deep research capabilities.
Insider Trading
Monitors buying and selling of company shares by executives, directors, and other insiders who may have unique insights into the company's prospects.

Investor Care

Shares Dilution (1Y)0.06%
Diluted EPS (TTM)18.89

Financial Health

Current Ratio2.15
Debt/Equity0.1

Summary of Latest Earnings Report from Global Health

Summary of Global Health's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.

Last updated: May 25

The management of Global Health Limited provided an optimistic outlook for the future during the Q4 FY25 earnings conference call, emphasizing their commitment to expanding healthcare services and infrastructure. Key forward-looking points include:

  1. Bed Capacity Expansion: Management plans to add approximately 1,000 beds over the next 2 years, with particular focus on the Noida facility, which will have a capacity of 550 beds and is set to become operational in Q2 FY26.

  2. New Hospital Projects: The company announced the establishment of three large-format greenfield hospitals in Mumbai, Pitampura, and Guwahati, enhancing access to high-quality tertiary care in high-growth regions.

  3. Financial Performance: For the fiscal year 2025, total consolidated income reached INR 37,714 million with a 13% year-on-year growth. EBITDA rose to INR 9,562 million, a 9% increase, resulting in a strong EBITDA margin of 25.4%. Profit after tax stood at INR 4,813 million, with an adjusted profit after tax of INR 5,186 million (up 9%).

  4. Future Capex Plans: The company has earmarked a total capital expenditure of around INR 4,000 crores to support the expansion, which includes capacity additions, technology upgrades, and the construction of new facilities over the next few years.

  5. Strong Cash Position: Global Health ended the fiscal year with a net cash surplus of INR 8,123 million, which positions them well to pursue their growth plans.

  6. Quality Commitment: They continue to invest in modern technology and skilled clinicians, ensuring high standards of patient care and advanced treatment options, such as CAR-T cell therapies and robotic surgeries.

Overall, management is confident that these initiatives will drive sustained growth and enhance their competitive positioning in the healthcare sector.

Last updated: May 25

Major Questions and Answers from the Q&A Section:

1. Question: "Could you please repeat the capex numbers? I just missed out on the total capex for the beds. Did you say INR 4,000 crores?"

Answer: "Yes, I said INR 4,000 crores."


2. Question: "Could you give a sense of how many transplants have been done in this quarter and in FY25, and how have those grown on a year-on-year basis?"

Answer: "I don't have the exact number on hand, but it's worth noting we crossed 250 kidney transplants at Lucknow. We perform various types of transplants in Gurugram, Lucknow, and Patna, but for specific numbers, our Investor Relations team will provide further details."


3. Question: "How are you seeing the competitive intensity across your major markets?"

Answer: "There's been an increase in competition from various players expanding into our markets. However, it largely benefits the industry by enhancing standards. Gurgaon has evolved into a medical hub, attracting talent and patients, which lifts all players. We believe this trend will positively affect Lucknow and Kanpur too."


4. Question: "Should we assume Lucknow and Patna will mostly remain cash-heavy regarding payer mix?"

Answer: "Yes, about 90% of our payer mix in Lucknow and Patna comes from cash plus TPA, with only a small share from schemes. We aim to serve those patients gradually, without drastically altering our cash payer focus."


5. Question: "What are your ARPOB growth expectations?"

Answer: "We plan to implement tariff hikes selectively to cover inflationary costs. Historically, ARPOB growth is expected to remain in the low to mid-single digits, similar to pre-pandemic levels."


6. Question: "What's the capex projected for the Pitampura unit?"

Answer: "The capex for Pitampura is INR 600 crores, and it's our portion due to our joint venture structure. This will be backloaded as most expenses arise post-construction."


7. Question: "What's the census bed count in our developing hospital units?"

Answer: "We have about 600 beds in Lucknow and 320 in Patna, totaling roughly 930 census beds across our developing hospitals."


8. Question: "Will you be sharing revenues or rentals in the DLF and Pitampura projects?"

Answer: "Yes, both will involve revenue-sharing agreements or rentals, depending on the commercial arrangements with the landowners."


9. Question: "What impact did Mahakumbh have on operations?"

Answer: "While Mahakumbh generated some patient influx, it generally leads to a dip in elective surgeries. We observed such impacts in previous festivals and believe it likely negatively affected this quarter's elective procedures."


10. Question: "Why was the gross margin for matured hospitals down?"

Answer: "Margins fluctuated based on specialty mix affecting costs. Year-on-year, EBITDA margins were stable at around 24.5%, so minor variances occur, especially with increased clinician costs. Full-year data provides a clearer picture compared to quarterly variations."

Share Holdings

Understand Global Health ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Share Holding Details

As of 2025-03-31
Shareholder NameHolding %
NARESH TREHAN33.03%
DUNEARN INVESTMENTS (MAURITIUS) PTE LTD14.86%
SUNIL SACHDEVA11.27%
RJ CORP LIMITED6.59%
GOVERNMENT PENSION FUND GLOBAL3.3%
KOTAK INDIA EQ CONTRA FUND2.93%
INVESCO INDIA AGGRESSIVE HYBRID FUND2.76%
POLARIS HEALTHCARE INVESTMENTS PTE LTD1.86%
UTI-FLEXI CAP FUND1.18%
NOVO HOLDINGS A/S1.01%
RKM FAMILY TRUST0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Is Global Health Better than it's peers?

Detailed comparison of Global Health against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.

Ticker
Name
Mkt Cap
Revenue
Price %, 1M
Returns, 1Y
P/E
P/S
Rev 1-Yr
Inc 1-Yr
MAXHEALTHMax Healthcare InstituteHospital1.11 LCr6.7 kCr+1.49%+47.11%109.6516.51+24.67%-4.60%
APOLLOHOSPApollo Hospitals EnterprisesHospital98.87 kCr21.31 kCr-1.71%+17.27%73.294.64+15.13%+64.06%
FORTISFortis HealthcareHospital56.98 kCr7.62 kCr+8.49%+68.17%69.117.48+12.17%+42.06%
NHNarayana HrudayalayaHospital35.63 kCr5.48 kCr-2.22%+49.28%45.446.51+8.88%+1.56%
KIMSKrishna Institute of Medical SciencesHospital26.18 kCr2.9 kCr+1.03%+80.96%68.919.02+18.28%+4.60%
HCGHealthCare Global EnterprisesHospital7.68 kCr2.16 kCr-3.56%+51.51%117.153.55+15.26%+178.69%

Sector Comparison: MEDANTA vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

MEDANTA metrics compared to Healthcare

CategoryMEDANTAHealthcare
PE63.3739.22
PS8.807.06
Growth12.6 %-1.3 %
67% metrics above sector average

Performance Comparison

MEDANTA vs Healthcare (2023 - 2025)

MEDANTA is underperforming relative to the broader Healthcare sector and has declined by 2.2% compared to the previous year.

Key Insights
  • 1. MEDANTA is among the Top 5 Hospital companies by market cap.
  • 2. The company holds a market share of 5.8% in Hospital.
  • 3. In last one year, the company has had an above average growth that other Hospital companies.

Income Statement for Global Health

Standalone figures (in Rs. Crores) /
Consolidated figures (in Rs. Crores) /

Balance Sheet for Global Health

Standalone figures (in Rs. Crores) /
Consolidated figures (in Rs. Crores) /

Cash Flow for Global Health

Consolidated figures (in Rs. Crores) /
Standalone figures (in Rs. Crores) /

What does Global Health Limited do?

Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in New Delhi, India.

Industry Group:Healthcare Services
Employees:9,052
Website:www.medanta.org